Xoma | XOMA - Operating Expenses


Xoma reported $22.84M in Operating Expenses for its fiscal quarter ending in September of 2024.





Operating Expenses Change Date
AbbVie USD 10.81B 13.45B Dec/2025
Agenus USD 19.81M 293.94M Dec/2025
Agios Pharmaceuticals USD 141.54M 11.8M Dec/2025
Ardelyx USD 120.12M 14.46M Dec/2025
aTyr Pharma USD 85.61M 58.67M Dec/2025
BioMarin Pharmaceutical USD 676.18M 131.65M Dec/2025
Celldex Therapeutics USD 87.27M 511.09M Dec/2025
Curis USD 9.02M 23.01M Dec/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Emergent BioSolutions USD 555.9M 242.7M Jun/2023
Incyte USD 1.12B 3.53B Dec/2025
MacroGenics USD 53.32M 13.68M Dec/2025
Novartis USD 9.8B 61M Dec/2025
Novartis USD 9.8B 23M Dec/2025
Pfizer USD 12.91B 79.89B Dec/2025
Prothena USD 27.23M 14.95M Dec/2025
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Xoma USD 22.84M 1.67M Sep/2024